Daré Bioscience, Inc. (DARE)
0.8015
-0.02
(-2.24%)
USD |
NASDAQ |
Aug 24, 16:00
0.8277
+0.03
(+3.27%)
Pre-Market: 08:29
Daré Bioscience Enterprise Value : 6.305M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 6.305M |
| August 21, 2026 | 6.584M |
| August 20, 2026 | 6.422M |
| August 19, 2026 | 6.652M |
| August 18, 2026 | 5.80M |
| August 17, 2026 | 6.437M |
| August 14, 2026 | 8.254M |
| August 13, 2026 | 14.93M |
| August 12, 2026 | 15.99M |
| August 11, 2026 | 15.99M |
| August 10, 2026 | 14.78M |
| August 07, 2026 | 15.38M |
| August 06, 2026 | 14.32M |
| August 05, 2026 | 14.47M |
| August 04, 2026 | 14.47M |
| August 03, 2026 | 13.56M |
| July 31, 2026 | 12.65M |
| July 30, 2026 | 12.96M |
| July 29, 2026 | 11.74M |
| July 28, 2026 | 12.12M |
| July 27, 2026 | 14.17M |
| July 24, 2026 | 13.56M |
| July 23, 2026 | 13.26M |
| July 22, 2026 | 12.65M |
| July 21, 2026 | 13.11M |
| Date | Value |
|---|---|
| July 20, 2026 | 14.47M |
| July 17, 2026 | 23.88M |
| July 16, 2026 | 23.58M |
| July 15, 2026 | 25.55M |
| July 14, 2026 | 25.55M |
| July 13, 2026 | 25.85M |
| July 10, 2026 | 24.79M |
| July 09, 2026 | 25.55M |
| July 08, 2026 | 24.94M |
| July 07, 2026 | 25.24M |
| July 06, 2026 | 25.70M |
| July 02, 2026 | 25.85M |
| July 01, 2026 | 26.15M |
| June 30, 2026 | 26.15M |
| June 29, 2026 | 19.24M |
| June 26, 2026 | 19.09M |
| June 25, 2026 | 17.78M |
| June 24, 2026 | 18.95M |
| June 23, 2026 | 18.80M |
| June 22, 2026 | 18.51M |
| June 18, 2026 | 20.26M |
| June 17, 2026 | 18.95M |
| June 16, 2026 | 19.38M |
| June 15, 2026 | 17.49M |
| June 12, 2026 | 18.07M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Nektar Therapeutics | 1.967B |
| Elite Pharmaceuticals, Inc. | 278.03M |
| Eton Pharmaceuticals, Inc. | 1.825B |
| ANI Pharmaceuticals, Inc. | 1.938B |
| Corcept Therapeutics, Inc. | 13.00B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.983M |
| Revenue (Quarterly) | 0.1875M |
| Total Expenses (Quarterly) | 3.170M |
| EPS Diluted (Quarterly) | -0.2003 |
| Gross Profit Margin (Quarterly) | -294.5% |
| Profit Margin (Quarterly) | -1.59K% |
| Earnings Yield | -98.02% |
| Normalized Earnings Yield | -98.02 |